Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Arizton Advisory & Intelligence | PRODUCT CODE: 1208901

Cover Image

PUBLISHER: Arizton Advisory & Intelligence | PRODUCT CODE: 1208901

In Vitro Diagnostics Market - Global Outlook & Forecast 2023-2028

PUBLISHED:
PAGES: 402 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4200
PDF (5 User License)
USD 4999
PDF (Corporate User License)
USD 5999

Add to Cart

The global in vitro diagnostics market size is expected to grow at a CAGR of 3.26% during 2022-2028

MARKET INSIGHTS

The IVD market offers advanced, cost-effective, and fast tools that enable precise diagnosis and point-of-care testing or self-testing. The market has moved from conventional instruments to advanced analyzers that need a small volume of samples and high-throughput screening methodologies. These advances, combined with AI and cloud technology, revolutionize the in vitro diagnostics market. The low-volume sample analysis, automation, high-throughput analysis, rapid analysis times, small footprint, low cost, portability, and disposability are key trends in the IVD market.

MARKET TRENDS & OPPORTUNITIES

Advances in Molecular Diagnostics Transforming the Future of Healthcare

The healthcare industry witnessed high development and growth in invitro diagnostics over the past decade. Advances in molecular diagnostics are dramatically improving medical treatment outcomes in current times. Due to drug failure in clinical trials and regulatory barriers, bio-pharmaceutical companies are turning toward new medical solutions at the molecular level and molecular diagnostics. In addition, next-generation sequencing and clustered regularly interspaced short palindromic repeats (CRISPER) technology significantly improve molecular diagnostics for oncology and infectious diseases care. Such factors are expected to lead the in vitro diagnostics market in the future.

Increasing Product Launches & Mergers & Acquisitions in IVD

IVD diagnostics is among the biggest industries to witness several product launches in recent years. The increasing demand for new diagnostics tests forces us to develop new solutions. Currently, the IVD players are operating in a world that designs, develops, manufactures, and sells best-in-class solutions. COVID-19 is one of the best periods where several companies have come forward to develop rapid test kits to detect coronavirus.

In the first half of 2021, IVD companies reported high revenues due to COVID-19 testing. However, in the year's second half, many companies experienced low demand for COVID-19 testing, resulting in decreased COVID-19 product revenue. In the same period, to increase the production and expansion of distribution networks, IVD companies adopted M&A strategies. To prepare for COVID-19, some major and emerging IVD companies have turned to M&As to increase their diagnostic testing portfolio. These acquisitions witnessed the in vitro diagnostics market expansion and portfolio expansion.

A large patient population with chronic and infectious diseases drives the demand for IVD solutions and fuels market growth.

Chronic diseases such as cancer, diabetes, cardiovascular diseases, and others are public health concerns worldwide, resulting in high demand for diagnostic services. In addition, infectious diseases, such as HIV, COVID-19, influenza, staphylococcus, respiratory syncytial virus, and others, pose significant demand for diagnostic services and fuel market growth.

The adoption of advanced technologies in IVD drives significant IVD testing worldwide without experiencing the burden of time and cost. Moreover, they have increased the efficiency of diagnostics and delivered the most accurate results that accelerate market growth. Advances, such as a new generation of IVD products with AI and the digital platform, provide newer dimensions in the global in vitro diagnostics market.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCTS AND SERVICES

The reagent and consumables are the largest segments, accounting for 66.47% of the global in vitro diagnostics market in 2022. Reagents and consumables are used in IVD procedures as a medium and transporter of specimens of patients with medical conditions for diagnosis, treatments, and monitoring. The reoccurring use of reagents and consumables is driving the market growth. Innovation in consumables, especially reagents, is low compared to analyzers. Some companies do come up with new types of reagents for unique products. For instance, Sysmex, a Japanese company, developed a concentrated reagent for hematology analyzers. These concentrated reagents are gaining traction in the market, especially in developed countries. This is helping the company to gain market share. End-users are shifting toward concentrated reagents, which have more benefits than conventional reagents.

Segmentation By Product & Services

  • Reagents and Consumables
  • Instruments/ Analyzers & Software
  • Services

INSIGHTS BY TECHNOLOGY

The global in vitro diagnostics market is segmented into immuno & clinical chemistry, molecular testing, hematology, microbiology & cytology, point- and others by technology. In 2022, the immune & clinical chemistry segment accounted for 45.26% market share of the global IVD market and dominated the other segments. Immunoassay and clinical chemistry are technologies that experience high usage in IVD. These technologies are mostly used to diagnose infectious and chronic diseases that significantly burden global healthcare services. The patient population with chronic and infectious diseases drives the segmental growth of immunochemistry-based IVD solutions. Furthermore, clinical chemistry has wide applications in detecting cancer, diabetes, heart disease, renal disease, liver disorders, and other health conditions that accelerate segmental growth.

Segmentation By Technology

  • Immuno and Clinical Chemistry
  • Molecular Diagnostics
  • Hematology
  • Microbiology and Cytology
  • Others Technology

INSIGHTS BY APPLICATION

In 2022, in vitro diagnostics applications for infectious diseases accounted for 46.95% market share. The global IVD market application is segmented into infectious diseases, diabetes, cardiology, oncology, autoimmune diseases, nephrology, drug testing, and others by application. During the COVID-19 pandemic, more than 3 to 4 billion tests were conducted worldwide, which fueled the growth of the in-vitro diagnostics market. In addition, HIV, influenza, respiratory syncytial virus, and other infectious diseases drive the demand for IVD and boost industry growth. With the increasing burden of infectious diseases, the demand for diagnosis and treatment continues to rise, thus driving the demand for IVD solutions. In recent years, the development in technologies and increasing integration of new technologies for infectious disease diagnosis have led the market to witness high revenue generation through the infectious diseases segment.

Segmentation By Application

  • Infectious Diseases
  • Diabetes
  • Cardiology
  • Oncology
  • Autoimmune Diseases
  • Nephrology
  • Drug Testing
  • Others

INSIGHTS BY END-USERS

The standard reference labs dominated the end-user segment in the global in vitro diagnostics market and was valued at USD 36 billion in 2022 and is expected to grow impressively by 2028. Standard reference laboratories offer several types of IVD services. In recent years, standard reference laboratories have rapidly expanded in LMICs to offer numerous tests and deliver high market growth through adopting new technologies and product offerings. Standard reference laboratories expand their network in a particular region or concentrated areas and deliver easy access to diagnostic services at affordable prices. In addition, the broad range of diagnosis services increases access to several tests that attract a high consumer base and generate significant revenue. In 2022, the standard reference labs segment accounted for 34.21% of the global IVD market.

Hospitals are the primary source and first point of contact for disease diagnosis and cure. In contrast, hospital-associated laboratories account for the high number of IVD practices and drive segmental growth. Globally, the number of hospitals and associated laboratories, growing infrastructure, and increasing healthcare expenditure are some factors that increase the demand for IVD practices through hospitals.

Segmentation By End-Users

  • Standard Reference Labs
  • Hospital-Affiliated Labs
  • Individuals
  • Clinics
  • Others

GEOGRAPHICAL ANALYSIS

In 2022, North America dominated the global IVD market accounting for a 39.90% share. A large patient population base with high healthcare expenditures accelerates the region's market growth. In addition, the awareness of disease diagnosis, such as point-of-care, early detection, and preventive health check-ups, are some factors that majorly and positively impact the industry growth in the region. More than 60% to 80% of the regional population have chronic conditions that demand diagnostics services. Expenditure on healthcare services in the region accounted for approximately USD 4.3 trillion and above in 2021, which grew by 2.7% from 2020, indicating a high potential for market growth. Some leading companies, such as Abbott, BD, Bio-Rad Laboratories, and Biomerieux SA, have higher market penetration in the region, especially in the US. They are increasing access to IVD components and accounting for high revenue generation in the country.

Europe is one of the leading and major regions for the IVD market, which accounts for a significant demand for IVD solutions. The factors responsible for the increasing demand for IVD solutions are the growing aging population in the region, with chronic and infectious diseases driving the high demand for IVD solutions. Across Europe, more than 25,000 pathologists are available, while the UK accounts for 40 pathologists per million population.

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Russia
    • Spain
    • Italy
    • UK
  • APAC
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Singapore
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa

COMPETITIVE LANDSCAPE

The leading players in the global in vitro diagnostics market are F Hoffmann-La Roche, Abbott, Thermo Fisher Scientific, and Siemens Healthineers, which are competing with rapidly emerging market players. Vendors are increasing their industry market share through inorganic growth and a constant product launch, helping the vendors acquire new customers. Abbot is one of the leading companies in the global in vitro diagnostics market and is a pioneer in point-of-care diagnostics with a comprehensive portfolio of tests and systems. Its diagnostic products segment offers core laboratory analyzers and biomarkers (clinical chemistry), immunoassay, hematology, and transfusion. In 2021, the company achieved around USD 15.6 billion in revenue, respectively.

Recent Developments in The Global In Vitro Diagnostics Market

  • In March 2020, Abbott's rapid diagnostic segment launched a molecular test solution to detect COVID-19 with its ID NOW rapid POC in the US.
  • Hoffmann-La Roche invested significantly in R&D activities to develop innovative IVD test solutions. For instance, in FY2019, the company invested about $12.86 billion in R&D activities.
  • In July 2019, Siemens Healthineers completed the acquisition of Minicare B.V. Minicare is developing technology for point-of-care immunoassay testing. The business is being integrated into the Diagnostics segment and will allow Siemens Healthineers to strengthen its portfolio in the rapid diagnostics domain.

Key Company Profiles

  • Abbott
  • Danaher
  • F. Hoffmann-La Roche
  • Siemens Healthineers
  • Thermo Fisher Scientific

Other Prominent Vendors

  • Atomo Diagnostics
  • Accelerate Diagnostics
  • Agilent Technologies
  • altona Diagnostics
  • Amoy Diagnostics
  • ARKRAY
  • AccuBioTech
  • Agappe Diagnostics
  • BD
  • Bio-Rad Laboratories
  • Balio diagnostics
  • B&E BIO-TECHNOLOGY
  • BIOMERIEUX
  • bioLytical Laboratories
  • Biosynex
  • Biocartis
  • Biocept
  • Biohit Oyj
  • Biomerica
  • Biosystems
  • Bioway Biological Technology
  • Boule Diagnostics
  • Cupid Limited
  • CareDx
  • Chembio Diagnostics
  • CLINDIAG SYSTEMS
  • CONTEC MEDICAL SYSTEMS
  • Convergent Technologies
  • CPC Diagnostics
  • CPM Scientifica
  • CellaVision
  • DIALAB
  • Dexcom
  • DiaSorin
  • Diagon
  • Diatron
  • DIRUI
  • Drucker Diagnostics
  • EDAN Instruments
  • EKF Diagnostics Holdings
  • ELITechGroup
  • Erba Diagnostics
  • Genetron Holdings
  • Genrui Biotech
  • Hologic
  • High Technology
  • HORIBA
  • Linear Chemicals
  • Illumina
  • INTEC
  • J. Mitra & Co.
  • Kilpest India Limited
  • Maccura Biotechnology
  • Medsource Ozone Biomedicals
  • Meril Life Sciences
  • MP Biomedicals
  • Nanjing Synthgene Medical Technology
  • NIHON KOHDEN
  • Norma Instruments
  • NOWDiagnostics
  • Ortho Clinical Diagnostics
  • OPKO Health
  • OraSure Technologies
  • Perkin Elmer
  • Prestige Diagnostics
  • QIAGEN
  • Quidel
  • Sysmex
  • Salofa Oy
  • SEASUN BIOMATERIALS
  • Sekisui Diagnostics
  • SFRI
  • Shenzhen Dymind Biotechnology
  • Shenzhen iCubio Biomedical Technology
  • Shenzhen Mindray Bio-Medical Electronics
  • SHENZHEN PROKAN ELECTRONICS
  • Shenzhen Landwind Medical
  • Sinocare
  • SPINREACT
  • SureScreen Diagnostics
  • The Binding Site Group
  • Trinity Biotech
  • Trivitron Healthcare
  • Xiamen Biotime Biotechnology
  • Zhejiang Orient Gene Biotech

KEY QUESTIONS ANSWERED:

  • 1. How big is the In Vitro Diagnostics Market?
  • 2. What is the growth rate of the in vitro diagnostics market?
  • 3. Who are the key players in the global in vitro diagnostics market?
  • 4. Which region holds the most significant global in vitro diagnostics market share?
  • 5. What are the growing trends in the in vitro diagnostics market?
Product Code: ARZ230116

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

  • 4.1 MARKET DEFINITION
    • 4.1.1 INCLUSIONS
    • 4.1.2 EXCLUSIONS
    • 4.1.3 MARKET ESTIMATION CAVEATS
  • 4.2 BASE YEAR
  • 4.3 SCOPE OF THE STUDY
    • 4.3.1 MARKET BY PRODUCT & SERVICES:
    • 4.3.2 MARKET BY TECHNOLOGY
    • 4.3.3 MARKET BY APPLICATION
    • 4.3.4 MARKET BY END-USERS
    • 4.3.5 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

  • 5.1 KEY CAVEATS
  • 5.2 CURRENCY CONVERSION
  • 5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 PREMIUM INSIGHTS

  • 7.1 OVERVIEW

8 INTRODUCTION

  • 8.1 OVERVIEW

9 MARKET OPPORTUNITIES & TRENDS

  • 9.1 ADVANCES IN MOLECULAR DIAGNOSTICS TRANSFORMING THE FUTURE OF HEALTHCARE
  • 9.2 INCREASED DEMAND FOR COMPANION DIAGNOSTICS IN IVD
  • 9.3 INCREASING PRODUCT LAUNCHES & MERGERS & ACQUISITIONS IN IVD

10 MARKET GROWTH ENABLERS

  • 10.1 PRESENCE OF A SIGNIFICANT PATIENT POPULATION
  • 10.2 ADOPTION OF ADVANCED TECHNOLOGIES IN IVD
  • 10.3 COVID-19 IMPACT ON IVD MARKET

11 MARKET RESTRAINTS

  • 11.1 STRINGENT REGULATIONS AND ASSOCIATED CHALLENGES
  • 11.2 HIGH COST OF IVD
  • 11.3 LACK OF ACCESS TO DIAGNOSTIC SERVICES AND ASSOCIATED CHALLENGES

12 MARKET LANDSCAPE

  • 12.1 MARKET OVERVIEW
    • 12.1.1 INSIGHT BY PRODUCT & SERVICES
    • 12.1.2 INSIGHT BY TECHNOLOGY
    • 12.1.3 INSIGHT BY APPLICATION
    • 12.1.4 INSIGHT BY END-USERS
    • 12.1.5 INSIGHT BY GEOGRAPHY
  • 12.2 MARKET SIZE & FORECAST
  • 12.3 FIVE FORCES ANALYSIS
    • 12.3.1 THREAT OF NEW ENTRANTS
    • 12.3.2 BARGAINING POWER OF SUPPLIERS
    • 12.3.3 BARGAINING POWER OF BUYERS
    • 12.3.4 THREAT OF SUBSTITUTES
    • 12.3.5 COMPETITIVE RIVALRY

13 PRODUCT & SERVICES

  • 13.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 13.2 MARKET OVERVIEW
  • 13.3 REAGENTS AND CONSUMABLES
    • 13.3.1 MARKET OVERVIEW
    • 13.3.2 MARKET SIZE & FORECAST
    • 13.3.3 MARKET BY GEOGRAPHY
  • 13.4 INSTRUMENTS/ANALYZERS & SOFTWARE
    • 13.4.1 MARKET OVERVIEW
    • 13.4.2 MARKET SIZE & FORECAST
    • 13.4.3 MARKET BY GEOGRAPHY
  • 13.5 SERVICES
    • 13.5.1 MARKET OVERVIEW
    • 13.5.2 MARKET SIZE & FORECAST
    • 13.5.3 MARKET BY GEOGRAPHY

14 TECHNOLOGY

  • 14.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 14.2 MARKET OVERVIEW
  • 14.3 IMMUNO & CLINICAL CHEMISTRY
    • 14.3.1 MARKET OVERVIEW
    • 14.3.2 MARKET SIZE & FORECAST
    • 14.3.3 MARKET BY GEOGRAPHY
  • 14.4 MOLECULAR DIAGNOSTICS
    • 14.4.1 MARKET OVERVIEW
    • 14.4.2 MARKET SIZE & FORECAST
    • 14.4.3 MARKET BY GEOGRAPHY
  • 14.5 HEMATOLOGY
    • 14.5.1 MARKET OVERVIEW
    • 14.5.2 MARKET SIZE & FORECAST
    • 14.5.3 MARKET BY GEOGRAPHY
  • 14.6 MICROBIOLOGY & CYTOLOGY
    • 14.6.1 MARKET OVERVIEW
    • 14.6.2 MARKET SIZE & FORECAST
    • 14.6.3 MARKET BY GEOGRAPHY
  • 14.7 OTHERS
    • 14.7.1 MARKET OVERVIEW
    • 14.7.2 MARKET SIZE & FORECAST
    • 14.7.3 MARKET BY GEOGRAPHY

15 APPLICATION

  • 15.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 15.2 MARKET OVERVIEW
  • 15.3 INFECTIOUS DISEASES
    • 15.3.1 MARKET OVERVIEW
    • 15.3.2 MARKET SIZE & FORECAST
    • 15.3.3 MARKET BY GEOGRAPHY
  • 15.4 DIABETES
    • 15.4.1 MARKET OVERVIEW
    • 15.4.2 MARKET SIZE & FORECAST
    • 15.4.3 MARKET BY GEOGRAPHY
  • 15.5 CARDIOLOGY
    • 15.5.1 MARKET OVERVIEW
    • 15.5.2 MARKET SIZE & FORECAST
    • 15.5.3 MARKET BY GEOGRAPHY
  • 15.6 ONCOLOGY
    • 15.6.1 MARKET OVERVIEW
    • 15.6.2 MARKET SIZE & FORECAST
    • 15.6.3 MARKET BY GEOGRAPHY
  • 15.7 AUTOIMMUNE DISEASE
    • 15.7.1 MARKET OVERVIEW
    • 15.7.2 MARKET SIZE & FORECAST
    • 15.7.3 MARKET BY GEOGRAPHY
  • 15.8 NEPHROLOGY
    • 15.8.1 MARKET OVERVIEW
    • 15.8.2 MARKET SIZE & FORECAST
    • 15.8.3 MARKET BY GEOGRAPHY
  • 15.9 DRUG TESTING
    • 15.9.1 MARKET OVERVIEW
    • 15.9.2 MARKET SIZE & FORECAST
    • 15.9.3 MARKET BY GEOGRAPHY
  • 15.10 OTHERS
    • 15.10.1 MARKET OVERVIEW
    • 15.10.2 MARKET SIZE & FORECAST
    • 15.10.3 MARKET BY GEOGRAPHY

16 END-USERS

  • 16.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 16.2 MARKET OVERVIEW
  • 16.3 STANDARD REFERENCE LABS
    • 16.3.1 MARKET OVERVIEW
    • 16.3.2 MARKET SIZE & FORECAST
    • 16.3.3 MARKET BY GEOGRAPHY
  • 16.4 HOSPITAL-AFFILIATED LABS
    • 16.4.1 MARKET OVERVIEW
    • 16.4.2 MARKET SIZE & FORECAST
    • 16.4.3 MARKET BY GEOGRAPHY
  • 16.5 INDIVIDUALS
    • 16.5.1 MARKET OVERVIEW
    • 16.5.2 MARKET SIZE & FORECAST
    • 16.5.3 MARKET BY GEOGRAPHY
  • 16.6 CLINICS
    • 16.6.1 MARKET OVERVIEW
    • 16.6.2 MARKET SIZE & FORECAST
    • 16.6.3 MARKET BY GEOGRAPHY
  • 16.7 OTHERS
    • 16.7.1 MARKET OVERVIEW
    • 16.7.2 MARKET SIZE & FORECAST
    • 16.7.3 MARKET BY GEOGRAPHY

17 GEOGRAPHY

  • 17.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 17.2 GEOGRAPHIC OVERVIEW

18 NORTH AMERICA

  • 18.1 MARKET OVERVIEW
  • 18.2 MARKET SIZE & FORECAST
  • 18.3 PRODUCT & SERVICES
    • 18.3.1 MARKET SIZE & FORECAST
  • 18.4 TECHNOLOGY
    • 18.4.1 MARKET SIZE & FORECAST
  • 18.5 APPLICATION
    • 18.5.1 MARKET SIZE & FORECAST
  • 18.6 END-USER
    • 18.6.1 MARKET SIZE & FORECAST
  • 18.7 KEY COUNTRIES
    • 18.7.1 US: MARKET SIZE & FORECAST
    • 18.7.2 CANADA: MARKET SIZE & FORECAST

19 EUROPE

  • 19.1 MARKET OVERVIEW
  • 19.2 MARKET SIZE & FORECAST
  • 19.3 PRODUCT & SERVICES
    • 19.3.1 MARKET SIZE & FORECAST
  • 19.4 TECHNOLOGY
    • 19.4.1 MARKET SIZE & FORECAST
  • 19.5 APPLICATION
    • 19.5.1 MARKET SIZE & FORECAST
  • 19.6 END-USER
    • 19.6.1 MARKET SIZE & FORECAST
  • 19.7 KEY COUNTRIES
    • 19.7.1 GERMANY: MARKET SIZE & FORECAST
    • 19.7.2 FRANCE: MARKET SIZE & FORECAST
    • 19.7.3 RUSSIA: MARKET SIZE & FORECAST
    • 19.7.4 SPAIN: MARKET SIZE & FORECAST
    • 19.7.5 ITALY: MARKET SIZE & FORECAST
    • 19.7.6 UK: MARKET SIZE & FORECAST

20 APAC

  • 20.1 MARKET OVERVIEW
  • 20.2 MARKET SIZE & FORECAST
  • 20.3 PRODUCT & SERVICES
    • 20.3.1 MARKET SIZE & FORECAST
  • 20.4 TECHNOLOGY
    • 20.4.1 MARKET SIZE & FORECAST
  • 20.5 APPLICATION
    • 20.5.1 MARKET SIZE & FORECAST
  • 20.6 END-USER
    • 20.6.1 MARKET SIZE & FORECAST
  • 20.7 KEY COUNTRIES
    • 20.7.1 CHINA: MARKET SIZE & FORECAST
    • 20.7.2 JAPAN: MARKET SIZE & FORECAST
    • 20.7.3 INDIA: MARKET SIZE & FORECAST
    • 20.7.4 SOUTH KOREA: MARKET SIZE & FORECAST
    • 20.7.5 AUSTRALIA: MARKET SIZE & FORECAST
    • 20.7.6 INDONESIA: MARKET SIZE & FORECAST
    • 20.7.7 MALAYSIA MARKET SIZE & FORECAST
    • 20.7.8 SINGAPORE MARKET SIZE & FORECAST

21 LATIN AMERICA

  • 21.1 MARKET OVERVIEW
  • 21.2 MARKET SIZE & FORECAST
  • 21.3 PRODUCT & SERVICES
    • 21.3.1 MARKET SIZE & FORECAST
  • 21.4 TECHNOLOGY
    • 21.4.1 MARKET SIZE & FORECAST
  • 21.5 APPLICATION
    • 21.5.1 MARKET SIZE & FORECAST
  • 21.6 END-USER
    • 21.6.1 MARKET SIZE & FORECAST
  • 21.7 KEY COUNTRIES
    • 21.7.1 BRAZIL: MARKET SIZE & FORECAST
    • 21.7.2 MEXICO: MARKET SIZE & FORECAST
    • 21.7.3 ARGENTINA: MARKET SIZE & FORECAST

22 MIDDLE EAST & AFRICA

  • 22.1 MARKET OVERVIEW
  • 22.2 MARKET SIZE & FORECAST
  • 22.3 PRODUCT & SERVICES
    • 22.3.1 MARKET SIZE & FORECAST
  • 22.4 TECHNOLOGY
    • 22.4.1 MARKET SIZE & FORECAST
  • 22.5 APPLICATION
    • 22.5.1 MARKET SIZE & FORECAST
  • 22.6 END-USER
    • 22.6.1 MARKET SIZE & FORECAST
  • 22.7 KEY COUNTRIES
    • 22.7.1 TURKEY: MARKET SIZE & FORECAST
    • 22.7.2 SAUDI ARABIA: MARKET SIZE & FORECAST
    • 22.7.3 SOUTH AFRICA: MARKET SIZE & FORECAST

23 COMPETITIVE LANDSCAPE

  • 23.1 COMPETITION OVERVIEW
  • 23.2 MARKET SHARE ANALYSIS
    • 23.2.1 ABBOTT
    • 23.2.2 DANAHER
    • 23.2.3 F. HOFFMANN-LA ROCHE
    • 23.2.4 SIEMENS HEALTHINEERS
    • 23.2.5 THERMO FISHER SCIENTIFIC

24 KEY COMPANY PROFILES

  • 24.1 ABBOTT
    • 24.1.1 BUSINESS OVERVIEW
    • 24.1.2 PRODUCT OFFERINGS
    • 24.1.3 KEY STRATEGIES
    • 24.1.4 KEY STRENGTHS
    • 24.1.5 KEY OPPORTUNITIES
  • 24.2 DANAHER
    • 24.2.1 BUSINESS OVERVIEW
    • 24.2.2 PRODUCT OFFERINGS
    • 24.2.3 KEY STRATEGIES
    • 24.2.4 KEY STRENGTHS
    • 24.2.5 KEY OPPORTUNITIES
  • 24.3 F. HOFFMANN-LA ROCHE
    • 24.3.1 BUSINESS OVERVIEW
    • 24.3.2 PRODUCT OFFERINGS
    • 24.3.3 KEY STRATEGIES
    • 24.3.4 KEY STRENGTHS
    • 24.3.5 KEY OPPORTUNITIES
  • 24.4 SIEMENS HEALTHINEERS
    • 24.4.1 BUSINESS OVERVIEW
    • 24.4.2 PRODUCT OFFERINGS
    • 24.4.3 KEY STRATEGIES
    • 24.4.4 KEY STRENGTHS
    • 24.4.5 KEY OPPORTUNITIES
  • 24.5 THERMO FISHER SCIENTIFIC
    • 24.5.1 BUSINESS OVERVIEW
    • 24.5.2 PRODUCT OFFERINGS
    • 24.5.3 KEY STRATEGIES
    • 24.5.4 KEY STRENGTHS
    • 24.5.5 KEY OPPORTUNITIES

25 OTHER PROMINENT VENDORS

  • 25.1 ATOMO DIAGNOSTICS
    • 25.1.1 BUSINESS OVERVIEW
    • 25.1.2 PRODUCT OFFERINGS
  • 25.2 ACCELERATE DIAGNOSTICS
    • 25.2.1 BUSINESS OVERVIEW
    • 25.2.2 PRODUCT OFFERINGS
  • 25.3 AGILENT TECHNOLOGIES
    • 25.3.1 BUSINESS OVERVIEW
    • 25.3.2 PRODUCT OFFERINGS
  • 25.4 ALTONA DIAGNOSTICS
    • 25.4.1 BUSINESS OVERVIEW
    • 25.4.2 PRODUCT OFFERINGS
  • 25.5 AMOY DIAGNOSTICS
    • 25.5.1 BUSINESS OVERVIEW
    • 25.5.2 PRODUCT OFFERINGS
  • 25.6 ARKRAY
    • 25.6.1 BUSINESS OVERVIEW
    • 25.6.2 PRODUCT OFFERINGS
  • 25.7 ACCUBIOTECH
    • 25.7.1 BUSINESS OVERVIEW
    • 25.7.2 PRODUCT OFFERINGS
  • 25.8 AGAPPE DIAGNOSTICS
    • 25.8.1 BUSINESS OVERVIEW
    • 25.8.2 PRODUCT OFFERINGS
  • 25.9 BD
    • 25.9.1 BUSINESS OVERVIEW
    • 25.9.2 PRODUCT OFFERINGS
  • 25.10 BIO-RAD LABORATORIES
    • 25.10.1 BUSINESS OVERVIEW
    • 25.10.2 PRODUCT OFFERINGS
  • 25.11 BALIO DIAGNOSTICS
    • 25.11.1 BUSINESS OVERVIEW
    • 25.11.2 PRODUCT OFFERINGS
  • 25.12 B&E BIO-TECHNOLOGY
    • 25.12.1 BUSINESS OVERVIEW
    • 25.12.2 PRODUCT OFFERINGS
  • 25.13 BIOMERIEUX
    • 25.13.1 BUSINESS OVERVIEW
    • 25.13.2 PRODUCT OFFERINGS
  • 25.14 BIOLYTICAL LABORATORIES
    • 25.14.1 BUSINESS OVERVIEW
    • 25.14.2 PRODUCT OFFERINGS
  • 25.15 BIOSYNEX
    • 25.15.1 BUSINESS OVERVIEW
    • 25.15.2 PRODUCT OFFERINGS
  • 25.16 BIOCARTIS
    • 25.16.1 BUSINESS OVERVIEW
    • 25.16.2 PRODUCT OFFERINGS
  • 25.17 BIOCEPT
    • 25.17.1 BUSINESS OVERVIEW
    • 25.17.2 PRODUCT OFFERINGS
  • 25.18 BIOHIT OYJ
    • 25.18.1 BUSINESS OVERVIEW
    • 25.18.2 PRODUCT OFFERINGS
  • 25.19 BIOMERICA
    • 25.19.1 BUSINESS OVERVIEW
    • 25.19.2 PRODUCT OFFERINGS
  • 25.20 BIOSYSTEM
    • 25.20.1 BUSINESS OVERVIEW
    • 25.20.2 PRODUCT OFFERINGS
  • 25.21 BIOWAY BIOLOGICAL TECHNOLOGY
    • 25.21.1 BUSINESS OVERVIEW
    • 25.21.2 PRODUCT OFFERINGS
  • 25.22 BOULE DIAGNOSTICS
    • 25.22.1 BUSINESS OVERVIEW
    • 25.22.2 PRODUCT OFFERINGS
  • 25.23 CUPID LIMITED
    • 25.23.1 BUSINESS OVERVIEW
    • 25.23.2 PRODUCT OFFERINGS
  • 25.24 CAREDX
    • 25.24.1 BUSINESS OVERVIEW
    • 25.24.2 PRODUCT OFFERINGS
  • 25.25 CHEMBIO DIAGNOSTICS
    • 25.25.1 BUSINESS OVERVIEW
    • 25.25.2 PRODUCT OFFERINGS
  • 25.26 CLINDIAG SYSTEMSA
    • 25.26.1 BUSINESS OVERVIEW
    • 25.26.2 PRODUCT OFFERINGS
  • 25.27 CONTEC MEDICAL SYSTEMS
    • 25.27.1 BUSINESS OVERVIEW
    • 25.27.2 PRODUCT OFFERINGS
  • 25.28 CONVERGENT TECHNOLOGIES
    • 25.28.1 BUSINESS OVERVIEW
    • 25.28.2 PRODUCT OFFERINGS
  • 25.29 CPC DIAGNOSTICS
    • 25.29.1 BUSINESS OVERVIEW
    • 25.29.2 PRODUCT OFFERINGS
  • 25.30 CPM SCIENTIFICA
    • 25.30.1 BUSINESS OVERVIEW
    • 25.30.2 PRODUCT OFFERINGS
  • 25.31 CELLAVISION
    • 25.31.1 BUSINESS OVERVIEW
    • 25.31.2 PRODUCT OFFERINGS
  • 25.32 DIALAB
    • 25.32.1 BUSINESS OVERVIEW
    • 25.32.2 PRODUCT OFFERINGS
  • 25.33 DEXCOM
    • 25.33.1 BUSINESS OVERVIEW
    • 25.33.2 PRODUCT OFFERINGS
  • 25.34 DIASORIN
    • 25.34.1 BUSINESS OVERVIEW
    • 25.34.2 PRODUCT OFFERINGS
  • 25.35 DIAGON
    • 25.35.1 BUSINESS OVERVIEW
    • 25.35.2 PRODUCT OFFERINGS
  • 25.36 DIATRON
    • 25.36.1 BUSINESS OVERVIEW
    • 25.36.2 PRODUCT OFFERINGS
  • 25.37 DIRUI
    • 25.37.1 BUSINESS OVERVIEW
    • 25.37.2 PRODUCT OFFERINGS
  • 25.38 DRUCKER DIAGNOSTICS
    • 25.38.1 BUSINESS OVERVIEW
    • 25.38.2 PRODUCT OFFERINGS
  • 25.39 EDAN INSTRUMENTS
    • 25.39.1 BUSINESS OVERVIEW
    • 25.39.2 PRODUCT OFFERINGS
  • 25.40 EKF DIAGNOSTICS HOLDING
    • 25.40.1 BUSINESS OVERVIEW
    • 25.40.2 PRODUCT OFFERINGS
  • 25.41 ELITECHGROUP
    • 25.41.1 BUSINESS OVERVIEW
    • 25.41.2 PRODUCT OFFERINGS
  • 25.42 ERBA DIAGNOSTICS
    • 25.42.1 BUSINESS OVERVIEW
    • 25.42.2 PRODUCT OFFERINGS
  • 25.43 GENETRON HOLDINGS
    • 25.43.1 BUSINESS OVERVIEW
    • 25.43.2 PRODUCT OFFERINGS
  • 25.44 GENRUI BIOTECH
    • 25.44.1 BUSINESS OVERVIEW
    • 25.44.2 PRODUCT OFFERINGS
  • 25.45 HOLOGIC
    • 25.45.1 BUSINESS OVERVIEW
    • 25.45.2 PRODUCT OFFERINGS
  • 25.46 HIGH TECHNOLOGY
    • 25.46.1 BUSINESS OVERVIEW
    • 25.46.2 PRODUCT OFFERINGS
  • 25.47 HORIBA
    • 25.47.1 BUSINESS OVERVIEW
    • 25.47.2 PRODUCT OFFERINGS
  • 25.48 LINEAR CHEMICALS
    • 25.48.1 BUSINESS OVERVIEW
    • 25.48.2 PRODUCT OFFERINGS
  • 25.49 ILLUMINA
    • 25.49.1 BUSINESS OVERVIEW
    • 25.49.2 PRODUCT OFFERINGS
  • 25.50 INTEC
    • 25.50.1 BUSINESS OVERVIEW
    • 25.50.2 PRODUCT OFFERINGS
  • 25.51 J. MITRA & CO.
    • 25.51.1 BUSINESS OVERVIEW
    • 25.51.2 PRODUCT OFFERINGS
  • 25.52 KILPEST INDIA LIMITED
    • 25.52.1 BUSINESS OVERVIEW
    • 25.52.2 PRODUCT OFFERINGS
  • 25.53 MACCURA BIOTECHNOLOGY
    • 25.53.1 BUSINESS OVERVIEW
    • 25.53.2 PRODUCT OFFERINGS
  • 25.54 MEDSOURCE OZONE BIOMEDICALS
    • 25.54.1 BUSINESS OVERVIEW
    • 25.54.2 PRODUCT OFFERINGS
  • 25.55 MERIL LIFE SCIENCES
    • 25.55.1 BUSINESS OVERVIEW
    • 25.55.2 PRODUCT OFFERINGS
  • 25.56 MP BIOMEDICALS
    • 25.56.1 BUSINESS OVERVIEW
    • 25.56.2 PRODUCT OFFERINGS
  • 25.57 NANJING SYNTHGENE MEDICAL TECHNOLOGY
    • 25.57.1 BUSINESS OVERVIEW
    • 25.57.2 PRODUCT OFFERINGS
  • 25.58 NIHON KOHDEN
    • 25.58.1 BUSINESS OVERVIEW
    • 25.58.2 PRODUCT OFFERINGS
  • 25.59 NORMA INSTRUMENTS
    • 25.59.1 BUSINESS OVERVIEW
    • 25.59.2 PRODUCT OFFERINGS
  • 25.60 NOWDIAGNOSTICS
    • 25.60.1 BUSINESS OVERVIEW
    • 25.60.2 PRODUCT OFFERINGS
  • 25.61 ORTHO CLINICAL DIAGNOSTICS
    • 25.61.1 BUSINESS OVERVIEW
    • 25.61.2 PRODUCT OFFERINGS
  • 25.62 OPKO HEALTH (BIOREFERENCE HEALTH)
    • 25.62.1 BUSINESS OVERVIEW
    • 25.62.2 PRODUCT OFFERINGS
  • 25.63 ORASURE TECHNOLOGIES
    • 25.63.1 BUSINESS OVERVIEW
    • 25.63.2 PRODUCT OFFERINGS
  • 25.64 PERKIN ELMER
    • 25.64.1 BUSINESS OVERVIEW
    • 25.64.2 PRODUCT OFFERINGS
  • 25.65 PRESTIGE DIAGNOSTICS
    • 25.65.1 BUSINESS OVERVIEW
    • 25.65.2 PRODUCT OFFERINGS
  • 25.66 QIAGEN
    • 25.66.1 BUSINESS OVERVIEW
    • 25.66.2 PRODUCT OFFERINGS
  • 25.67 QUIDEL
    • 25.67.1 BUSINESS OVERVIEW
    • 25.67.2 PRODUCT OFFERINGS
  • 25.68 SYSMEX
    • 25.68.1 BUSINESS OVERVIEW
    • 25.68.2 PRODUCT OFFERINGS
  • 25.69 SALOFA OY
    • 25.69.1 BUSINESS OVERVIEW
    • 25.69.2 PRODUCT OFFERINGS
  • 25.70 SEASUN BIOMATERIALS
    • 25.70.1 BUSINESS OVERVIEW
    • 25.70.2 PRODUCT OFFERINGS
  • 25.71 SEKISUI DIAGNOSTICS
    • 25.71.1 BUSINESS OVERVIEW
  • 25.72 SFRI
    • 25.72.1 BUSINESS OVERVIEW
    • 25.72.2 PRODUCT OFFERINGS
  • 25.73 SHENZHEN DYMIND BIOTECHNOLOGY
    • 25.73.1 BUSINESS OVERVIEW
    • 25.73.2 PRODUCT OFFERINGS
  • 25.74 SHENZHEN ICUBIO BIOMEDICAL TECHNOLOGY
    • 25.74.1 BUSINESS OVERVIEW
    • 25.74.2 PRODUCT OFFERINGS
  • 25.75 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS
    • 25.75.1 BUSINESS OVERVIEW
    • 25.75.2 PRODUCT OFFERINGS
  • 25.76 SHENZHEN PROKAN ELECTRONICS
    • 25.76.1 BUSINESS OVERVIEW
    • 25.76.2 PRODUCT OFFERINGS
  • 25.77 SHENZHEN LANDWIND MEDICAL
    • 25.77.1 BUSINESS OVERVIEW
    • 25.77.2 PRODUCT OFFERINGS
  • 25.78 SINOCARE
    • 25.78.1 BUSINESS OVERVIEW
    • 25.78.2 PRODUCT OFFERINGS
  • 25.79 SPINREACT
    • 25.79.1 BUSINESS OVERVIEW
    • 25.79.2 PRODUCT OFFERINGS
  • 25.80 SURESCREEN DIAGNOSTICS
    • 25.80.1 BUSINESS OVERVIEW
    • 25.80.2 PRODUCT OFFERINGS
  • 25.81 THE BINDING SITE GROUP
    • 25.81.1 BUSINESS OVERVIEW
    • 25.81.2 PRODUCT OFFERINGS
  • 25.82 TRINITY BIOTECH
    • 25.82.1 BUSINESS OVERVIEW
    • 25.82.2 PRODUCT OFFERINGS
  • 25.83 TRIVITRON HEALTHCARE
    • 25.83.1 BUSINESS OVERVIEW
    • 25.83.2 PRODUCT OFFERINGS
  • 25.84 XIAMEN BIOTIME BIOTECHNOLOGY
    • 25.84.1 BUSINESS OVERVIEW
    • 25.84.2 PRODUCT OFFERINGS
  • 25.85 ZHEJIANG ORIENT GENE BIOTECH
    • 25.85.1 BUSINESS OVERVIEW
    • 25.85.2 PRODUCT OFFERINGS

26 REPORT SUMMARY

  • 26.1 KEY TAKEAWAYS
  • 26.2 STRATEGIC RECOMMENDATIONS

27 QUANTITATIVE SUMMARY

  • 27.1 MARKET BY GEOGRAPHY
  • 27.2 MARKET BY PRODUCT & SERVICES
  • 27.3 MARKET BY TECHNOLOGY
  • 27.4 MARKET BY APPLICATION
  • 27.5 MARKET BY END-USERS
  • 27.6 PRODUCT & SERVICES: MARKET BY GEOGRAPHY
    • 27.6.1 REAGENTS & CONSUMABLES: MARKET BY GEOGRAPHY
    • 27.6.2 INSTRUMENTS/ANALYZERS & SOFTWARE: MARKET BY GEOGRAPHY
    • 27.6.3 SERVICES: MARKET BY GEOGRAPHY
  • 27.7 TECHNOLOGY: MARKET BY GEOGRAPHY
    • 27.7.1 IMMUNO & CLINICAL CHEMISTRY: MARKET BY GEOGRAPHY
    • 27.7.2 MOLECULAR DIAGNOSTICS: MARKET BY GEOGRAPHY
    • 27.7.3 HEMATOLOGY: MARKET BY GEOGRAPHY
    • 27.7.4 MICROBIOLOGY & CYTOLOGY: MARKET BY GEOGRAPHY
    • 27.7.5 OTHER TECHNOLOGIES: MARKET BY GEOGRAPHY
  • 27.8 APPLICATION: MARKET BY GEOGRAPHY
    • 27.8.1 INFECTIOUS DISEASES: MARKET BY GEOGRAPHY
    • 27.8.2 DIABETES: MARKET BY GEOGRAPHY
    • 27.8.3 CARDIOLOGY: MARKET BY GEOGRAPHY
    • 27.8.4 ONCOLOGY: MARKET BY GEOGRAPHY
    • 27.8.5 AUTOIMMUNE DISEASES: MARKET BY GEOGRAPHY
    • 27.8.6 NEPHROLOGY: MARKET BY GEOGRAPHY
    • 27.8.7 DRUG TESTING: MARKET BY GEOGRAPHY
    • 27.8.8 OTHER APPLICATIONS: MARKET BY GEOGRAPHY
  • 27.9 END-USERS: MARKET BY GEOGRAPHY
    • 27.9.1 STANDARD REFERENCE LABS: MARKET BY GEOGRAPHY
    • 27.9.2 HOSPITAL AFFILIATED LABS: MARKET BY GEOGRAPHY
    • 27.9.3 INDIVIDUALS: MARKET BY GEOGRAPHY
    • 27.9.4 CLINICS: MARKET BY GEOGRAPHY
    • 27.9.5 OTHER END-USERS: MARKET BY GEOGRAPHY

28 APPENDIX

  • 28.1 ABBREVIATIONS
Product Code: ARZ230116

LIST OF EXHIBITS

  • EXHIBIT 1 SEGMENTATION OF GLOBAL IN-VITRO DIAGNOSTICS MARKET
  • EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022
  • EXHIBIT 3 CURRENT & EMERGING MARKET TRENDS
  • EXHIBIT 4 GLOBAL IN-VITRO DIAGNOSTICS MARKET SEGMENTATION
  • EXHIBIT 5 MAJOR TRENDS IN IN-VITRO DIAGNOSTICS INDUSTRY
  • EXHIBIT 6 IMPACT OF ADVANCES IN MOLECULAR DIAGNOSTICS TRANSFORMING THE FUTURE OF HEALTHCARE
  • EXHIBIT 7 IMPACT OF INCREASED DEMAND FOR COMPANION DIAGNOSTICS IN IVD
  • EXHIBIT 8 SOME OF THE KEY TECHNOLOGY TRENDS IN COMPANION DIAGNOSTICS
  • EXHIBIT 9 IMPACT OF INCREASING PRODUCT LAUNCHES & MERGERS & ACQUISITIONS IN IVD
  • EXHIBIT 10 IMPACT OF PRESENCE OF A SIGNIFICANT PATIENT POPULATION
  • EXHIBIT 11 CANCER NEW CASES STATISTICS 2020 BY REGIONS
  • EXHIBIT 12 GLOBAL RARE DISEASES STATISTICS OVERVIEW
  • EXHIBIT 13 IMPACT OF ADOPTION OF ADVANCED TECHNOLOGIES IN IVD
  • EXHIBIT 14 CLINICAL LABORATORY ENGAGEMENT WITH AI 2018
  • EXHIBIT 15 IMPACT OF COVID-19 IMPACTS ON IVD ACCEPTANCE
  • EXHIBIT 16 UNICEF SARS-COV-2 RRT-PCR TEST FOR AUTOMATED USE 2020 SEPTEMBER -2021 (MILLION)
  • EXHIBIT 17 IMPACT OF STRINGENT REGULATION AND ASSOCIATED CHALLENGES
  • EXHIBIT 18 IMPACT OF HIGH COST OF IVD
  • EXHIBIT 19 IMPACT OF LACK OF ACCESS TO DIAGNOSTIC SERVICES AND ASSOCIATED CHALLENGES
  • EXHIBIT 20 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028
  • EXHIBIT 21 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028
  • EXHIBIT 22 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028
  • EXHIBIT 23 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022-2028
  • EXHIBIT 24 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028
  • EXHIBIT 25 GLOBAL IN-VITRO DIAGNOSTICS MARKET 2022-2028 ($ BILLION)
  • EXHIBIT 26 FIVE FORCES ANALYSIS 2022
  • EXHIBIT 27 INCREMENTAL GROWTH BY PRODUCT &SERVICES 2022 & 2028
  • EXHIBIT 28 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028
  • EXHIBIT 29 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCTS & SERVICES: MARKET OVERVIEW
  • EXHIBIT 30 GLOBAL IVD MARKET BY PRODUCTS & SERVICES: INCREMENTAL GROWTH
  • EXHIBIT 31 GLOBAL IVD MARKET BY PRODUCTS & SERVICES: ABSOLUTE GROWTH
  • EXHIBIT 32 GLOBAL IVD MARKET BY REAGENTS & CONSUMABLES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 33 GLOBAL IVD MARKET BY REAGENTS & CONSUMABLES 2022-2028 ($ BILLION)
  • EXHIBIT 34 GLOBAL IVD MARKET BY INSTRUMENT/ANALYZERS & SOFTWARE: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 35 GLOBAL IVD MARKET BY INSTRUMENTS/ ANALYZERS & SOFTWARE 2022-2028 ($ BILLION)
  • EXHIBIT 36 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY SERVICES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 37 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY SERVICES 2022-2028 ($ BILLION)
  • EXHIBIT 38 INCREMENTAL GROWTH BY TECHNOLOGY 2022 & 2028
  • EXHIBIT 39 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028
  • EXHIBIT 40 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY: MARKET OVERVIEW
  • EXHIBIT 41 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY: INCREMENTAL GROWTH
  • EXHIBIT 42 GLOBAL IVD MARKET BY TECHNOLOGY: ABSOLUTE GROWTH
  • EXHIBIT 43 DIABETES ESTIMATED & PROJECTED PATIENT POPULATION: OPPORTUNITIES FOR SELF-MONITORING TEST
  • EXHIBIT 44 GLOBAL IVD MARKET BY IMMUNO & CLINICAL CHEMISTRY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 45 GLOBAL IVD MARKET BY IMMUNO & CLINICAL CHEMISTRY 2022-2028 ($ BILLION)
  • EXHIBIT 46 GLOBAL IVD MARKET BY MOLECULAR DIAGNOSTICS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 47 GLOBAL IVD MARKET BY MOLECULAR DIAGNOSTICS 2022-2028 ($ BILLION)
  • EXHIBIT 48 GLOBAL IVD MARKET BY HEMATOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 49 GLOBAL IVD MARKET BY HEMATOLOGY 2022-2028 ($ BILLION)
  • EXHIBIT 50 COMPARISON OF CURRENT & DEVELOPING DIAGNOSTICS BY COST & COMPLEXITY 2021
  • EXHIBIT 51 GLOBAL IVD MARKET BY MICROBIOLOGY & CYTOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 52 GLOBAL IVD MARKET BY MICROBIOLOGY & CYTOLOGY 2022-2028 ($ BILLION)
  • EXHIBIT 53 SYSMEX CORPORATION HEMOSTASIS BUSINESS SALE 2018 TO 2021 ($ BILLION)
  • EXHIBIT 54 ADVANTAGES OF URINALYSIS OVER BLOOD TESTING
  • EXHIBIT 55 GLOBAL IVD MARKET BY OTHER TECHNOLOGIES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 56 GLOBAL IVD MARKET BY OTHER TECHNOLOGY 2022-2028 ($ BILLION)
  • EXHIBIT 57 INCREMENTAL GROWTH BY APPLICATIONS 2022 & 2028
  • EXHIBIT 58 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028
  • EXHIBIT 59 GLOBAL IVD MARKET BY APPLICATION: MARKET OVERVIEW
  • EXHIBIT 60 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION: INCREMENTAL GROWTH
  • EXHIBIT 61 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION: ABSOLUTE GROWTH
  • EXHIBIT 62 DAILY COVID-19 CASES 2020-2022
  • EXHIBIT 63 HIV PATIENT POPULATION BY REGION 2021 (MILLION)
  • EXHIBIT 64 GLOBAL IVD MARKET BY INFECTIOUS DISEASES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 65 GLOBAL IVD MARKET BY INFECTIOUS DISEASES 2022-2028 ($ BILLION)
  • EXHIBIT 66 NO. OF PEOPLE WITH DIABETES & PER IDF REGION 2021-2045 (20-79 YEARS)
  • EXHIBIT 67 DIABETES PREVALENCE BY INCOME OF COUNTRIES 2021 & 2025
  • EXHIBIT 68 GLOBAL IVD MARKET BY DIABETES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 69 GLOBAL IVD MARKET BY DIABETES 2022-2028 ($ BILLION)
  • EXHIBIT 70 GLOBAL IVD MARKET BY CARDIOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 71 GLOBAL IVD MARKET BY CARDIOLOGY 2022-2028 ($ BILLION)
  • EXHIBIT 72 NEW CANCER CASES BY TYPE 2020
  • EXHIBIT 73 GLOBAL IVD MARKET BY ONCOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 74 GLOBAL IVD MARKET BY ONCOLOGY 2022-2028 ($ BILLION)
  • EXHIBIT 75 GLOBAL IVD MARKET BY AUTOIMMUNE DISEASES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 76 GLOBAL IVD MARKET BY AUTOIMMUNE DISEASES 2022-2028 ($ BILLION)
  • EXHIBIT 77 GLOBAL EPIDEMIOLOGY OF CHRONIC KIDNEY DISEASE (CKD): AN UPDATE 2022
  • EXHIBIT 78 GLOBAL IVD MARKET BY NEPHROLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 79 GLOBAL IVD MARKET BY NEPHROLOGY 2022-2028 ($ BILLION)
  • EXHIBIT 80 COMPARISON OF RAPID & LAB-BASED DRUG SCREENING IN URINE SAMPLE BASED ON TURNAROUND TIME (MINUTES)
  • EXHIBIT 81 GLOBAL IVD MARKET BY DRUG TESTING: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 82 GLOBAL IVD MARKET BY DRUG TESTING 2022-2028 ($ BILLION)
  • EXHIBIT 83 GLOBAL IVD MARKET BY OTHER APPLICATIONS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 84 GLOBAL IVD MARKET BY OTHER APPLICATION 2022-2028 ($ BILLION)
  • EXHIBIT 85 INCREMENTAL GROWTH BY END-USERS 2022 & 2028
  • EXHIBIT 86 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022-2028
  • EXHIBIT 87 GLOBAL IVD MARKET BY END-USERS: MARKET OVERVIEW
  • EXHIBIT 88 GLOBAL IVD MARKET BY END-USERS: INCREMENTAL GROWTH
  • EXHIBIT 89 GLOBAL IVD MARKET BY END-USER: ABSOLUTE GROWTH
  • EXHIBIT 90 GLOBAL IVD MARKET BY STANDARD REFERENCE LABS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 91 GLOBAL IVD MARKET BY STANDARD REFERENCE LABS 2022-2028 ($ BILLION)
  • EXHIBIT 92 GLOBAL IVD MARKET BY HOSPITAL AFFILIATED LABS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 93 GLOBAL IVD MARKET BY HOSPITAL AFFILIATED LABS 2022-2028 ($ BILLION)
  • EXHIBIT 94 GLOBAL IVD MARKET BY INDIVIDUAL: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 95 GLOBAL IVD MARKET BY INDIVIDUALS 2022-2028 ($ BILLION)
  • EXHIBIT 96 GLOBAL IVD MARKET BY CLINICS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 97 GLOBAL IVD MARKET BY CLINICS 2022-2028 ($ BILLION)
  • EXHIBIT 98 GLOBAL IVD MARKET BY OTHER END-USERS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 99 GLOBAL IVD MARKET BY OTHER END-USERS 2022-2028 ($ BILLION)
  • EXHIBIT 100 INCREMENTAL GROWTH BY GEOGRAPHY 2022 & 2028
  • EXHIBIT 101 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028
  • EXHIBIT 102 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY: MARKET OVERVIEW
  • EXHIBIT 103 PRODUCT LIFE CYCLE IN VARIOUS REGIONS - IVD MARKET
  • EXHIBIT 104 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
  • EXHIBIT 105 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
  • EXHIBIT 106 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES
  • EXHIBIT 107 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 108 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET 2022-2028 ($ BILLION)
  • EXHIBIT 109 INCREMENTAL GROWTH IN NORTH AMERICA 2022 & 2028
  • EXHIBIT 110 US: HEALTH CONDITIONS & PREVALENCE 2019 TO 2022
  • EXHIBIT 111 IN-VITRO DIAGNOSTICS MARKET IN THE US 2022-2028 ($ BILLION)
  • EXHIBIT 112 IN-VITRO DIAGNOSTICS MARKET IN CANADA 2022-2028 ($ BILLION)
  • EXHIBIT 113 EUROPE IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES
  • EXHIBIT 114 POTENTIAL EFFECT OF IVDR ON LDTS IN CLINICAL LABS
  • EXHIBIT 115 EUROPE IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 116 EUROPE IN-VITRO DIAGNOSTICS MARKET 2022-2028 ($ BILLION)
  • EXHIBIT 117 INCREMENTAL GROWTH IN EUROPE 2022 & 2028
  • EXHIBIT 118 GERMANY: PEOPLE LIVING WITH HIV AND NEW HIV INFECTION CASES 2015 TO 2020
  • EXHIBIT 119 IN-VITRO DIAGNOSTICS MARKET IN GERMANY 2022-2028 ($ BILLION)
  • EXHIBIT 120 IN-VITRO DIAGNOSTICS MARKET IN FRANCE 2022-2028 ($ BILLION)
  • EXHIBIT 121 IN-VITRO DIAGNOSTICS MARKET IN RUSSIA 2022-2028 ($ BILLION)
  • EXHIBIT 122 IN-VITRO DIAGNOSTICS MARKET IN SPAIN 2022-2028 ($ BILLION)
  • EXHIBIT 123 IN-VITRO DIAGNOSTICS MARKET IN ITALY 2022-2028 ($ BILLION)
  • EXHIBIT 124 IN-VITRO DIAGNOSTICS MARKET IN THE UK 2022-2028 ($ BILLION)
  • EXHIBIT 125 APAC IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES
  • EXHIBIT 126 APAC IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 127 APAC IN-VITRO DIAGNOSTICS MARKET 2022-2028 ($ BILLION)
  • EXHIBIT 128 INCREMENTAL GROWTH IN APAC 2022 & 2028
  • EXHIBIT 129 IN-VITRO DIAGNOSTICS MARKET IN CHINA 2022-2028 ($ BILLION)
  • EXHIBIT 130 IN-VITRO DIAGNOSTICS MARKET JAPAN 2022-2028 ($ BILLION)
  • EXHIBIT 131 IN-VITRO DIAGNOSTICS MARKET IN INDIA 2022-2028 ($ BILLION)
  • EXHIBIT 132 IN-VITRO DIAGNOSTICS MARKET IN SOUTH KOREA 2022-2028 ($ BILLION)
  • EXHIBIT 133 IN-VITRO DIAGNOSTICS MARKET IN AUSTRALIA 2022-2028 ($ BILLION)
  • EXHIBIT 134 TOTAL HIV CASES IN INDONESIA 2010-2021
  • EXHIBIT 135 IN-VITRO DIAGNOSTICS MARKET IN INDONESIA 2022-2028 ($ BILLION)
  • EXHIBIT 136 IN-VITRO DIAGNOSTICS MARKET IN MALAYSIA 2022-2028 ($ BILLION)
  • EXHIBIT 137 IN-VITRO DIAGNOSTICS MARKET IN SINGAPORE 2022-2028 ($ BILLION)
  • EXHIBIT 138 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES
  • EXHIBIT 139 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 140 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET 2022-2028 ($ BILLION)
  • EXHIBIT 141 INCREMENTAL GROWTH IN LATIN AMERICA 2022 & 2028
  • EXHIBIT 142 IN-VITRO DIAGNOSTICS MARKET IN BRAZIL 2022-2028 ($ BILLION)
  • EXHIBIT 143 IN-VITRO DIAGNOSTICS MARKET MEXICO 2022-2028 ($ BILLION)
  • EXHIBIT 144 IN-VITRO DIAGNOSTICS MARKET ARGENTINA 2022-2028 ($ BILLION)
  • EXHIBIT 145 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES
  • EXHIBIT 146 MIDDLE EAST & AFRICA NATIONAL HIVST POLICY & IMPLEMENTATION 2020
  • EXHIBIT 147 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 148 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET 2022-2028 ($ BILLION)
  • EXHIBIT 149 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2022 & 2028
  • EXHIBIT 150 IN-VITRO DIAGNOSTICS MARKET IN TURKEY 2022-2028 ($ BILLION)
  • EXHIBIT 151 IN-VITRO DIAGNOSTICS MARKET SAUDI ARABIA 2022-2028 ($ BILLION)
  • EXHIBIT 152 IN-VITRO DIAGNOSTICS MARKET SOUTH AFRICA 2022-2028 ($ BILLION)
  • EXHIBIT 153 GLOBAL IVD MARKET DOMINANCE ANALYSIS
  • EXHIBIT 154 GLOBAL IVD MARKET DOMINANCE ANALYSIS
  • EXHIBIT 155 VENDORS OFFERING IVD SOLUTIONS: CAPABILITIES & EXPERTISE ASSESSMENT
  • EXHIBIT 156 MARKET SHARE & PENETRATION ANALYSIS BASED ON THE REVENUE OF THE MARKET PLAYERS 2020

LIST OF TABLES

  • TABLE 1 KEY CAVEATS
  • TABLE 2 CURRENCY CONVERSION 2015-2022
  • TABLE 3 LIST OF APPROVED/CLEARED COMPANION DIAGNOSTIC DEVICES (IVD)
  • TABLE 4 LEADING COMPANIES WITH NEW IVD PRODUCTS LAUNCHED 2021-2022
  • TABLE 5 LEADING COMPANIES WITH NEW IVD PRODUCTS LAUNCHED 2021-2022
  • TABLE 6 SARS-COV-2 DIAGNOSTICS TEST TYPE
  • TABLE 7 GLOBAL IVD REAGENTS AND CONSUMABLES MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 8 GLOBAL IVD REAGENTS AND CONSUMABLES MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 9 GLOBAL IVD INSTRUMENTS/ANALYZERS & SOFTWARE MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 10 GLOBAL IVD INSTRUMENTS/ANALYZERS & SOFTWARE MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 11 GLOBAL IVD SERVICES MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 12 GLOBAL IVD SERVICES MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 13 GLOBAL IVD IMMUNO & CLINICAL CHEMISTRY MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 14 GLOBAL IVD IMMUNO & CLINICAL CHEMISTRY MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 15 GLOBAL IVD MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 16 GLOBAL IVD MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 17 GLOBAL IVD HEMATOLOGY MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 18 GLOBAL IVD HEMATOLOGY MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 19 GLOBAL IVD MICROBIOLOGY & CYTOLOGY MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 20 GLOBAL IVD MICROBIOLOGY & CYTOLOGY MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 21 GLOBAL IVD OTHERS TECHNOLOGY MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 22 GLOBAL IVD OTHERS TECHNOLOGY MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 23 COVID-19 PATIENT POPULATION & TOTAL TEST PERFORMED 2020-2022
  • TABLE 24 GLOBAL IVD INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 25 GLOBAL IVD INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 26 UNDIAGNOSED DIABETES PATIENT POPULATION CLASSIFICATION BASED ON ECONOMIC STATUS OF COUNTRIES 2021
  • TABLE 27 GLOBAL IVD DIABETES MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 28 GLOBAL IVD DIABETES MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 29 GLOBAL IVD CARDIOLOGY MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 30 GLOBAL IVD CARDIOLOGY MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 31 GLOBAL IVD ONCOLOGY MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 32 GLOBAL IVD ONCOLOGY MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 33 GLOBAL IVD AUTOIMMUNE DISEASES MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 34 GLOBAL IVD AUTOIMMUNE DISEASES MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 35 GLOBAL CHRONIC KIDNEY FAILURE PATIENT POPULATION
  • TABLE 36 GLOBAL IVD NEPHROLOGY MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 37 GLOBAL IVD NEPHROLOGY MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 38 GLOBAL IVD DRUG TESTING MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 39 GLOBAL IVD DRUG TESTING MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 40 GLOBAL IVD OTHER APPLICATIONS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 41 GLOBAL IVD OTHER APPLICATIONS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 42 GLOBAL IVD STANDARD REFERENCE LABS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 43 GLOBAL IVD STANDARD REFERENCE LABS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 44 GLOBAL IVD HOSPITAL AFFILIATED LABS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 45 GLOBAL IVD HOSPITAL AFFILIATED LABS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 46 GLOBAL IVD INDIVIDUALS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 47 GLOBAL IVD INDIVIDUALS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 48 GLOBAL IVD CLINICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 49 GLOBAL IVD CLINICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 50 GLOBAL IVD OTHER END-USERS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 51 GLOBAL IVD OTHER END-USERS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 52 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 ($ BILLION)
  • TABLE 53 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 (%)
  • TABLE 54 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 ($ BILLION)
  • TABLE 55 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 (%)
  • TABLE 56 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028 ($ BILLION)
  • TABLE 57 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028 (%)
  • TABLE 58 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022-2028 ($ BILLION)
  • TABLE 59 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022-2028 (%)
  • TABLE 60 US: CANCER STATISTICS 2020
  • TABLE 61 EUROPE IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 ($ BILLION)
  • TABLE 62 EUROPE IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 (%)
  • TABLE 63 EUROPE IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 ($ BILLION)
  • TABLE 64 EUROPE IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 (%)
  • TABLE 65 EUROPE IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028 ($ BILLION)
  • TABLE 66 EUROPE IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028 (%)
  • TABLE 67 EUROPE IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022-2028 ($ BILLION)
  • TABLE 68 EUROPE IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022-2028 (%)
  • TABLE 69 APAC IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 ($ BILLION)
  • TABLE 70 APAC IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 (%)
  • TABLE 71 APAC IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 ($ BILLION)
  • TABLE 72 APAC IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 (%)
  • TABLE 73 APAC IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028 ($ BILLION)
  • TABLE 74 APAC IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028 (%)
  • TABLE 75 APAC IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022-2028 ($ BILLION)
  • TABLE 76 APAC IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022-2028 (%)
  • TABLE 77 COMMERCIAL RT-PCR ASSAY FOR SARS-COV-2 DIAGNOSIS IN MALAYSIA
  • TABLE 78 COVID-19 STATISTICS IN LATIN AMERICA (2019-2022)
  • TABLE 79 LATIN IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 ($ BILLION)
  • TABLE 80 LATIN IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 (%)
  • TABLE 81 LATIN IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 ($ BILLION)
  • TABLE 82 LATIN IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 (%)
  • TABLE 83 LATIN IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028 ($ BILLION)
  • TABLE 84 LATIN IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028 (%)
  • TABLE 85 LATIN IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022-2028 ($ BILLION)
  • TABLE 86 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022-2028 (%)
  • TABLE 87 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 ($ BILLION)
  • TABLE 88 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 (%)
  • TABLE 89 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 ($ BILLION)
  • TABLE 90 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 (%)
  • TABLE 91 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028 ($ BILLION)
  • TABLE 92 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028 (%)
  • TABLE 93 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022-2028 ($ BILLION)
  • TABLE 94 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022-2028 (%)
  • TABLE 95 COMPETITION AMONG MARKET PLAYERS BASED ON TECHNOLOGY
  • TABLE 96 COMPETITION AMONG MARKET PLAYERS BASED ON TECHNOLOGY ($ BILLION) 2020-2021
  • TABLE 97 ABBOTT DIAGNOSTIC SEGMENT REVENUE FROM 2019 - 2021 ($ MILLION)
  • TABLE 98 ABBOTT: MAJOR PRODUCT OFFERINGS
  • TABLE 99 DANAHER: MAJOR PRODUCT OFFERINGS
  • TABLE 100 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
  • TABLE 101 SIEMENS HEALTHINEERS: MAJOR PRODUCT OFFERINGS
  • TABLE 102 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
  • TABLE 103 ATOMO DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 104 ACCELERATE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 105 AGILENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
  • TABLE 106 ALTONA DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 107 AMOY DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 108 ARKRAY: MAJOR PRODUCT OFFERINGS
  • TABLE 109 ACCUBIOTECH: MAJOR PRODUCT OFFERINGS
  • TABLE 110 AGAPPE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 111 BD: MAJOR PRODUCT OFFERINGS
  • TABLE 112 BIO-RAD LABORATORIES: MAJOR PRODUCT OFFERINGS
  • TABLE 113 BALIO DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 114 B&E BIO-TECHNOLOGY: MAJOR PRODUCT OFFERINGS
  • TABLE 115 BIOMERIEUX: MAJOR PRODUCT OFFERINGS
  • TABLE 116 BIOLYTICAL LABORATORIES: MAJOR PRODUCT OFFERINGS
  • TABLE 117 BIOSYNEX: MAJOR PRODUCT OFFERINGS
  • TABLE 118 BIOCARTIS: MAJOR PRODUCT OFFERINGS
  • TABLE 119 BIOCEPT: MAJOR PRODUCT OFFERINGS
  • TABLE 120 BIOHIT OYJ: MAJOR PRODUCT OFFERINGS
  • TABLE 121 BIOMERICA: MAJOR PRODUCT OFFERINGS
  • TABLE 122 BIOSYSTEMS: MAJOR PRODUCT OFFERINGS
  • TABLE 123 BIOWAY BIOLOGICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS
  • TABLE 124 BOULE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 125 CUPID LIMITED: MAJOR PRODUCT OFFERINGS
  • TABLE 126 CAREDX: MAJOR PRODUCT OFFERINGS
  • TABLE 127 CHEMBIO DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 128 CLINDIAG SYSTEMS: MAJOR PRODUCT OFFERINGS
  • TABLE 129 CONTEC MEDICAL SYSTEMS: MAJOR PRODUCT OFFERINGS
  • TABLE 130 CONVERGENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
  • TABLE 131 CPC DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 132 CPM SCIENTIFICA: MAJOR PRODUCT OFFERINGS
  • TABLE 133 CELLAVISION: MAJOR PRODUCT OFFERINGS
  • TABLE 134 DIALAB: MAJOR PRODUCT OFFERINGS
  • TABLE 135 DEXCOM: MAJOR PRODUCT OFFERINGS
  • TABLE 136 DIASORIN: MAJOR PRODUCT OFFERINGS
  • TABLE 137 DIAGON: MAJOR PRODUCT OFFERINGS
  • TABLE 138 DIATRON: MAJOR PRODUCT OFFERINGS
  • TABLE 139 DIRUI: MAJOR PRODUCT OFFERINGS
  • TABLE 140 DRUCKER DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 141 EDAN INSTRUMENTS: MAJOR PRODUCT OFFERINGS
  • TABLE 142 EKF DIAGNOSTICS HOLDINGS: MAJOR PRODUCT OFFERINGS
  • TABLE 143 ELITECHGROUP: MAJOR PRODUCT OFFERINGS
  • TABLE 144 ERBA DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 145 GENETRON HOLDINGS: MAJOR PRODUCT OFFERINGS
  • TABLE 146 GENRUI BIOTECH: MAJOR PRODUCT OFFERINGS
  • TABLE 147 HOLOGIC: MAJOR PRODUCT OFFERINGS
  • TABLE 148 HIGH TECHNOLOGY: MAJOR PRODUCT OFFERINGS
  • TABLE 149 HORIBA: MAJOR PRODUCT OFFERINGS
  • TABLE 150 LINEAR CHEMICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 151 ILLUMINA: MAJOR PRODUCT OFFERINGS
  • TABLE 152 INTEC: MAJOR PRODUCT OFFERINGS
  • TABLE 153 J. MITRA & CO.: MAJOR PRODUCT OFFERINGS
  • TABLE 154 KILPEST INDIA LIMITED: MAJOR PRODUCT OFFERINGS
  • TABLE 155 MACCURA BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS
  • TABLE 156 MEDSOURCE OZONE BIOMEDICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 157 MERIL LIFE SCIENCES: MAJOR PRODUCT OFFERINGS
  • TABLE 158 MP BIOMEDICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 159 NANJING SYNTHGENE MEDICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS
  • TABLE 160 NIHON KOHDEN: MAJOR PRODUCT OFFERINGS
  • TABLE 161 NORMA INSTRUMENTS: MAJOR PRODUCT OFFERINGS
  • TABLE 162 NOWDIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 163 ORTHO CLINICAL DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 164 OPKO HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 165 ORASURE TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
  • TABLE 166 PERKIN ELMER: MAJOR PRODUCT OFFERINGS
  • TABLE 167 PRESTIGE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 168 QIAGEN: MAJOR PRODUCT OFFERINGS
  • TABLE 169 QUIDEL: MAJOR PRODUCT OFFERINGS
  • TABLE 170 SYSMEX: MAJOR PRODUCT OFFERINGS
  • TABLE 171 SALOFA OY: MAJOR PRODUCT OFFERINGS
  • TABLE 172 SEASUN BIOMATERIALS: MAJOR PRODUCT OFFERINGS
  • TABLE 173 SEKISUI DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 174 SFRI: MAJOR PRODUCT OFFERINGS
  • TABLE 175 SHENZHEN DYMIND BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS
  • TABLE 176 SHENZHEN ICUBIO BIOMEDICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS
  • TABLE 177 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS: MAJOR PRODUCT OFFERINGS
  • TABLE 178 SHENZHEN PROKAN ELECTRONICS: MAJOR PRODUCT OFFERINGS
  • TABLE 179 SHENZHEN LANDWIND MEDICAL: MAJOR PRODUCT OFFERINGS
  • TABLE 180 SINOCARE: MAJOR PRODUCT OFFERINGS
  • TABLE 181 SPINREACT: MAJOR PRODUCT OFFERINGS
  • TABLE 182 SURESCREEN DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 183 THE BINDING SITE GROUP: MAJOR PRODUCT OFFERINGS
  • TABLE 184 TRINITY BIOTECH: MAJOR PRODUCT OFFERINGS
  • TABLE 185 TRIVITRON HEALTHCARE: MAJOR PRODUCT OFFERINGS
  • TABLE 186 XIAMEN BIOTIME BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS
  • TABLE 187 ZHEJIANG ORIENT GENE BIOTECH: MAJOR PRODUCT OFFERINGS
  • TABLE 188 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 189 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 190 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 ($ BILLION)
  • TABLE 191 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028 (%)
  • TABLE 192 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 ($ BILLION)
  • TABLE 193 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028 (%)
  • TABLE 194 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028 ($ BILLION)
  • TABLE 195 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 196 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022-2028 ($ BILLION)
  • TABLE 197 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022-2028 (%)
  • TABLE 198 REAGENTS & CONSUMABLES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 199 REAGENTS & CONSUMABLES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 200 INSTRUMENTS/ANALYZERS & SOFTWARE IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 201 INSTRUMENTS/ANALYZERS & SOFTWARE IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 202 SERVICES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 203 SERVICES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 204 IMMUNO & CLINICAL CHEMISTRY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 205 IMMUNO & CLINICAL CHEMISTRY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 206 MOLECULAR DIAGNOSTICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 207 MOLECULAR DIAGNOSTICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 208 HEMATOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 209 HEMATOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 210 MICROBIOLOGY & CYTOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 211 MICROBIOLOGY & CYTOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 212 OTHER TECHNOLOGIES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 213 OTHER TECHNOLOGIES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 214 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 215 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 216 DIABETES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 217 DIABETES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 218 CARDIOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 219 CARDIOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 220 ONCOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 221 ONCOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 222 AUTOIMMUNE DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 223 AUTOIMMUNE DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 224 NEPHROLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 225 NEPHROLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 226 DRUG TESTING IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 227 DRUG TESTING IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 228 OTHER APPLICATIONS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 229 OTHER APPLICATIONS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 230 STANDARD REFERENCE LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 231 STANDARD REFERENCE LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 232 HOSPITALS AFFILIATED LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 233 HOSPITALS AFFILIATED LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 234 INDIVIDUALS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 235 INDIVIDUALS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 236 CLINICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 237 CLINICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
  • TABLE 238 OTHER END-USERS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 ($ BILLION)
  • TABLE 239 OTHER END-USERS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028 (%)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!